Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

Exclusion Criteria

• •High risk or advanced proliferative diabetic retinopathy in the study eye as per reading Center
• •Active intraocular or periocular infection or active intraocular inflammation in the study eye
• •Uncontrolled glaucoma in the study eye defined as intraocular pressure (IOP) \> 25 millimeters mercury (mmHg)
• •Previous treatment with any anti-VEGF drugs or investigational drugs in the study eye in the last 3 months prior randomization
• •Stroke or myocardial infarction during the 6-month period prior to baseline